Nausea ranks as the most frequent initial symptom, often described as mild queasiness rather than severe vomiting
Your medical history is reviewed
Results published in The Lancet showed significant improvements in both weight and glycemic control (Rosenstock et al., 2023): Participants lost up to 16.9% of body weight (lower than the non-diabetic cohort, consistent with other medication studies) HbA1c reductions of up to 2.02 percentage points , bringing many participants into the normal range Significant improvements in fasting glucose and insulin sensitivity Phase 3 Trials Eli Lilly initiated Phase 3 clinical trials for retatrutide in late 2023
Its really about optimization
Information for prescribers Cautions/contraindications Hypersensitivity to the active substance or to any of the excipients (sodium phosphate dibasic heptahydrate, sodium chloride, concentrated hydrochloric acid and sodium hydroxide, glycerol, phenol, benzyl alcohol, water)
Semaglutide is administered just once a week through an easy-to-use injection